SmarT (Senlang Bio)

SmarT (Specific Multiple Antigen-Receptor T-cells) is an investigational autologous cell therapy developed by Hebei Senlang Biotechnology. It consists of T cells engineered with chimeric receptors designed to target tumor-associated antigens, most notably Claudin 18.2 (CLDN18.2) in the context of gastric and gastroesophageal junction adenocarcinomas. The "CAR-like" designation refers to a proprietary signaling architecture or manufacturing platform intended to improve the persistence and efficacy of the cells within the immunosuppressive microenvironment of solid tumors. In clinical trials, SmarT is frequently evaluated as part of a combination regimen alongside PD-1 checkpoint inhibitors and standard chemotherapy (such as the SOX regimen) to enhance objective response rates and progression-free survival in patients with advanced gastrointestinal cancers.

Other names

chimeric antigen receptor-like t-cellCAR-like T cellSpecific Multiple Antigen-Receptor T-cells